🔗 Share this article

As the US proceeds with unprecedented adjustments to its vaccination guidelines, a particular individual appears in a surprising turn: Høeg, a US-based sports physician and public health researcher who rose to prominence by casting doubt on COVID-19 vaccines during the pandemic and has concentrated on possible fatalities following COVID-19 vaccination in her recent position at the FDA.

Planned Shifts to Childhood Vaccine Schedule

Public health authorities were set to announce sweeping revisions to the pediatric immunization program earlier this month, bringing the US with the Danish vaccine program, it is understood – a major change that would place the US out of alignment with much of the world with insufficient data for improved outcomes. This reveal has been postponed until the coming year.

Instead of the top vaccines chief, Dr. Høeg is set to speak at the gathering. She was just designated temporary leader of the FDA’s CDER, the fifth individual to run the division this calendar year.

A New Direction at the Regulatory Body

The acting appointment could signify a strengthened alliance between the drug and biologics divisions as Høeg and Prasad strengthen their influence at the FDA – and it points to a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Høeg has repeatedly called for halting some childhood immunization guidelines in the US to become more in line with Denmark's approach, a country with comprehensive healthcare and a population about the size of the state of Wisconsin.

So far comments, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, head of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of pharmaceutical oversight.

Doubts Over Background

Dr. Høeg has little discernible track record in pharmaceutical research, approval processes or administrative roles, which has been standard for previous leaders of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a key advisor to the commissioner and the vaccine center since March.

“She doesn’t seem to have the necessary background” for overseeing the CDER, remarked a neurologist and psychiatrist. “She’s never run a randomized controlled trial. She is not versed in managing a large organization. She is not an expert in industry regulation.”

Former commissioners of the center would “be deeply familiar with regulatory frameworks and the research of drug development”, commented Janet Woodcock. “Objectively, she doesn’t have the kind of background that previous people who led CBER have had.”

The drug center has an vast portfolio at the agency, Woodcock emphasized.

“Everybody just zeroes in on the new drug program, but the generic drug division approves numerous off-brand pharmaceuticals. There’s a biosimilars division, over-the-counter program and other areas, and all of those have to be looked after,” Woodcock explained. “The area you neglect, that’s the thing that I always told people is going to cause problems.”

There is also, a major management aspect to the job, which oversees more than 5,000 personnel. “It is a massive management job, if you do it right,” the former official concluded.

Response and Contentious Policies

In response to inquiries about Dr. Høeg's credentials and whether this selection represents greater collaboration among FDA leaders on vaccines, a representative said that the “concerns are based on incorrect premises”.

“This background matches the duties of her position,” the spokesperson explained, citing the period Dr. Høeg spent guiding the agency head on “medication safety and approval science, including predictive safety algorithms and immunization monitoring”.

As acting director, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a contentious rapid therapy clearance system that reportedly concerned her former heads. “By what process are these medications being picked for this voucher program? Who takes the decisions?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the regulatory body right now.”

Broadly speaking, he said, “the agency looks to be trending towards more relaxed rules of pharmaceuticals, with the exception of immunizations.”

Established Past Work on Immunizations

Regarding vaccines, Dr. Høeg has a more documented, if problematic, track record, critics said. She released a study using non-validated volunteer-provided data to assess the incidence of heart inflammation following Covid immunization. She consulted for the state of Florida top health official Joseph Ladapo, who reportedly have altered data to suggest COVID-19 vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming administration featured revising guidelines for recently developed shots and discontinuing “optional” vaccines, she stated following the vote on a audio program. At the FDA, Dr. Høeg has according to sources floated the idea of preventing adolescent males from obtaining COVID-19 vaccinations.

“She is an all-around dogmatist who starts off with her conclusions and reverse-engineers to fit the evidence in a very disingenuous, untruthful manner,” Dr. Howard stated.

Consolidating Power and a “Revenge Tour”

Dr. Høeg aligned with other skeptics, {like|